Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01HKZ
|
|||
| Former ID |
DIB004927
|
|||
| Drug Name |
TSR-011
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 1/2 | [1] | |
| Company |
Tesaro
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C33H44FN5O3
|
|||
| Canonical SMILES |
CC(C)NC(=O)C1CCC(CC1)N2C3=C(C=CC(=C3)CN4CCC(CC4)C(C)(C)O)N=C2NC(=O)C5=CC=C(C=C5)F
|
|||
| InChI |
1S/C33H44FN5O3/c1-21(2)35-30(40)24-8-12-27(13-9-24)39-29-19-22(20-38-17-15-25(16-18-38)33(3,4)42)5-14-28(29)36-32(39)37-31(41)23-6-10-26(34)11-7-23/h5-7,10-11,14,19,21,24-25,27,42H,8-9,12-13,15-18,20H2,1-4H3,(H,35,40)(H,36,37,41)
|
|||
| InChIKey |
WSTUJEXAPHIEIM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1357920-84-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ALK tyrosine kinase receptor (ALK) | Target Info | Inhibitor | [2], [3] |
| KEGG Pathway | Non-small cell lung cancer | |||
| WikiPathways | Differentiation Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02048488) A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas. U.S. National Institutes ofHealth. | |||
| REF 2 | Treatment of ALK-positive non-small cell lung cancer. Arch Pathol Lab Med. 2012 Oct;136(10):1201-4. | |||
| REF 3 | National Cancer Institute Drug Dictionary (drug id 757983). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.